Table 3.

Summary of case-control studies assessing the VEGF polymorphisms in relation to risk of NSCLC

PolymorphismEthnicityCase-ControlGenotypeAssociation of Cancer Risk with Respect to VEGF GenotypeGenderORL95% CIU 95% CIReference No.
936 C > TCaucasian1,900/1,458(CT or TT) vs. CCNoAll1.050.871.27(39)
NoMale1.130.871.5
NoFemale0.990.271.29
-1498 C > TCaucasian1,900/1,458(CT or CC) vs. TTNoAll1.160.961.4(39)
NoMale1.070.811.4
NoFemale1.270.981.65
-634 G > CCaucasian1,900/1,458(CG or CC) vs. GGNoAll1.140.961.36(39)
Yes (increases risk, lung adenocarcinoma)Male1.270.991.63
NoFemale1.040.821.32
-1498T/-634C/936CCaucasian1,900/1,458Ref: -1498C/-634G/936CNoAll1.020.881.17(39)
NoMale1.150.941.42
NoFemale0.910.741.11
-1498T/-634G/936CCaucasian1,900/1,458Ref: -1498C/-634G/936CNoAll0.880.751.04(39)
Yes (decreases risk, lung adenocarcinoma)Male0.810.631.02
NoFemale0.930.741.17
-1498C/-634G/936TCaucasian1,900/1,458Ref: -1498C/-634G/936CNoAll0.980.741.31(39)
NoMale0.90.591.36
NoFemale1.040.691.55
-1498T/-634C/936TCaucasian1,900/1,458Ref: -1498C/-634G/936CNoAll1.140.841.55(39)
NoMale1.150.721.85
NoFemale1.040.691.57

Abbreviations: L, lower; U, upper; Ref, reference haplotype.